Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study

Investigational New Drugs

Volumn 22, Issue 4, 2004, Pages 481-487

  Firvida, José Luis ^a   Amenedo, Margarita ^b   Rodríguez, Rubén ^a   González, Ana ^b   Salgado, Mercedes ^a   Ramos, Manuel ^b   Losada, Gustavo ^b  

^a Servicio Gallego de Salud   (Spain)

^b Centro Oncologico de Galicia   (Spain)

Author keywords

docetaxel; fractionated cisplatin; non small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FRACTIONATION; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS; TIME FACTORS;

EID: 10244236556     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000036691.30244.46     Document Type: Article

References (28)

1. Evans TL, Lynch TJ, Jr.: Lung cancer. Oncologist 6(5): 407-414, 2001
2. Bengtson EM, Rigas JR: A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: Why we should look beyond platinum. Semin Oncol 26(5 Suppl 16): 1-6, 1999
3. Lynch TJ, Jr.: Review of two phase II randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 28(3 Suppl 9): 5-9, 2001
4. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, et al.: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13(3): 645-651, 1995
5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095-2103, 2000
6. Fossella FV: Docetaxel in the treatment of non-small cell lung cancer: Review of single-agent trials. Semin Oncol 26(5 Suppl 16): 17-23; discussion 41-12, 1999
7. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, van Meerbeek J, Wanders J, Franklin HR, Kaye S: Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70(2): 384-387, 1994
8. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, et al.: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12(6): 1238-1244, 1994
9. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12(6): 1232-1237, 1994
10. Georgoulias V: Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem 9(8): 869-877, 2002
11. Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15(3): 1071-1079, 1997
12. Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 15(2): 750-758, 1997
13. Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS, Kim HK: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 7(2): 114-119, 2002
14. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16(5): 1948-1953, 1998
15. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Grigoratou T, Palamidas P, Kouroussis C, Mavroudis D, Kakolyris S, Giannakakis T, Vlachonikolis J: Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: Early results of a randomized trial. Lung Cancer 34(Suppl4):S47-S51, 2001
16. Georgoulias V, Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou C, Vossos A, Agelidou M, Heras P, Tzannes S, Vlachonicolis J, Mavromanolakis E, Hatzidaki D: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. Ann Oncol 9(3): 331-334, 1998
17. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, Berille J: Docetaxel (Taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34(13): 2032-2036, 1998
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2): 92-98, 2002
19. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21(16): 3016-3024, 2003
20. Belani CP: Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol 29(3 Suppl 12): 4-9, 2002
21. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 21(9): 1752-1759, 2003
22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981
23. G. Guidelines for the reporting of adverse drug reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute; 1988
24. Kaplan ZL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
25. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9(9): 1618-1626, 1991
26. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 357(9267): 1478-1484, 2001
27. Niho S, Ohe Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Nishiwaki Y: Phase II study of docetaxel and cis-platin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 35(2): 209-214, 2002
28. Sweeney CJ, Zhu J, Sandier AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92(10): 2639-2647, 2001